cas 1446502-11-9, Enasidenib | Articles data

Articles about 1446502-11-9Total 11 be found

2,4,6-trisubstituted-1,3,5-s-triazine compound and preparation and application thereof
The invention provides a 2,4,6-trisubstituted-1,3,5-s-triazine compound as well as preparation and application thereof, and biguanide or dimethyl biguanide hydrochloride is used as an initial raw material to react with a cyano compound under an alkaline condition to prepare the 2,4,6-trisubstituted-1,3,5-s-triazine compound. The invention provides a simple and convenient synthetic method of a 2,4,6-trisubstituted-1,3,5-s-triazine compound, and the compound provided by the invention can be applied to preparation of an anti-myelogenous leukemia medicine, namely an enasidenib medicine. Compared with the prior art, the method for preparing the enasidenib has the advantages that two-step reaction is reduced, the use of a halogenating reagent is avoided, and the method is a green and environment-friendly chemical process. The structural formula I is shown in the specification.
-
(2021/10/05)

Preparation method of enasidenib
The invention discloses a preparation method of enasidenib. The method comprises the following steps: 6-(6-trifluoromethyl-2-yl)-1,3,5-triazine-2,4-dione is condensed with 1-amino-2-methyl-2-propanoland 2-trifluoromethyl-4-aminopyridine in sequence to generate the target compound enasidenib (I). The preparation method is simple in process, mild in condition, safe and environment-friendly, and provides a new way for industrial production.
-
Paragraph 0015; 0032-0033; 0036-0037

(2020/09/09)

TABLET COMPOSITIONS
Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol or a pharmaceutically acceptable salt thereof.
-
(2018/03/25)

COMBINATION THERAPY FOR TREATING MALIGNANCIES
Provided are methods and compositions for treating AML in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and an AML induction and consolidation therapy.
-
(2018/11/21)

METHODS OF PREPARING 6-(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIOLS AND 6-(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINES
Provided are methods of preparing compounds of formula (VIII) useful for treating cancer and intermediates of formula (I)
-
Paragraph 0073; 0078

(2017/02/28)

COMBINATION THERAPY FOR TREATING MALIGNANCIES
Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
-
(2017/05/02)

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
Provided are crystalline forms of 2-Methyl-l-[ (4-[ 6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2- yl)amino]propan-2-ol mesylate useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof said compound.
-
(2016/09/22)

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
Provided are compounds useful for treating cancer and methods of treating cancer, for example an advanced solid tumor, such as a glioma, or angioimmunoblastic T-cell lymphoma (AITL).
-
(2016/04/26)

CRYSTALLINE FORMS OF THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF
Provided are crystalline forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{ [2-(trifluoromethyl)pyridin-4-yl]amino }-1, 3, 5-triazin-2-yl)amino]propan-2-ol(COMPOUND 3), 2-methyl-1-[(4- [6-(trifluoromethyl)pyridin-2-yi]-6-{ [2-(trifluoromethyl)pyridin-4- yl]amino }-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate (COMPOUND 1) and use thereof.
-
(2015/02/25)

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.
-
(2015/02/25)

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
-
Page/Page column 134

(2013/07/19)